DNP Green Technology bags green chemistry pioneer Bioamber S.A.S


Pomacle/Minneapolis – US company DNP Green Technology and French Agroindustrie Recherches et Developpements (ARD) have restructured their successful joint venture Bioamber S.A.S, the world’s first company manufacturing the chemical building block succinic acid using a biotechnological CO2-consuming process from renewable instead petrochemical resources. According to the companies, DNP Green Technology acquired 100% of the shares in Bioamber, and ARD became a shareholder in DNP Green Technology, which will be renamed Bioamber Inc. „This was the right moment to restructure our joint venture“, said Jean‐Francois Huc, CEO of DNP Green Technology. „Our collaboration has evolved into a business which demands rapid commercialization of bio-based succinic acid, in order to take full advantage of our position as first to market. Both partners felt that this could best be achieved through DNP Green. According to both companies, Bioamber Inc will take over full responsibility of commercialization. ARD focus will be on process optimization in the plant and the scale up of a next-generation organism producing succinic acid.
In January, Bioamber had started a bio-succinic acid plant with an annual production capacity of 2,000 metric tons in Pomacle near Reims. According to Bioamber’s former managing director, Patrick Piot, Bioamber is targeting a EUR210m world market of approximately 30,000 metric tonnes per year that is expected to grow rapidly. Simple chemical conversion to 1.4 butane-diol opens up another market opportunity of 1.3 million tonnes per annum. Bioamber does not plan to build larger plants. Instead, the company’s business model is to outlicense the technology to industrial partners.
Several chemistry firms, including Mitsubishi Chemical Corp/Ajinomoto, Royal DSM/Roquette, and BASF/Purac, have also established fermentation processes to produce succinic acid with the help of metabolically engineered bacteria. While Mitsubishi and DSM are yet to produce on a pilot scale, German world market leaders BASF kicked off 2009 a 4,000 tonne/year commercial production plant with its partner Purac near Barcelona but the start of industrial production has been delayed, according to the companies.




Minneapolis/Banzancourt – Bioamber Inc. is one step closer to the environmental summit. The company's goal is to establish sustainable, "green" chemistry on an industrial scale. The French/US enterprise has now scaled up its...



Sophia Antipolis/ Madison – French NicOx S.A. and the global eye health specialist Bausch & Lomb have announced positive top-line results from their phase 2b dose finding study with BOL-303259-X, a nitric oxide-donating version...



Paris/Barcelona – French pharma company Sanofi strengthens its ties with the Spanish research institution CGR (Center for Genomic Regulation) in Barcelona. CGR stated on 12 March that the two partners agreed upon three years of...



Lyon – The sale of 1.6 million shares brought in €25.3m for French Adocia SAS during its IPO on the Euronext Paris. The price of €15.88 values the diabetes specialist at €96.1m at the upper end of the bookbuilding range. Late...



Pointing to a new study on Syngenta’s GM maize Bt11, France’s Environment Ministry has asked the European Commission to suspend authorisation for the use of the MON810 maize sold by US agri­biotech giant Monsanto as well. The...



Cambridge - Genzyme will shut the doors at its Cambridge R&D site by the end of the year, with up to 60 employees expected to lose their jobs. The move is part of an ongoing global restructuring of R&D by Sanofi, who purchased...



Lille – Shares of the French diabetes specialist Genfit S.A. almost doubled when the company published results of its Phase II study with the PPAR alpha and delta modulator GFT505. The compound has met the co-primary and...



Shares of the French diabetes specialist almost doubled when the companypublished results of its Phase II study with the PPAR alpha and deltamodulator GFT505. The compound has met the co-primary and secondaryendpoints while...



Bagneux - DBV Technologies is planning an IPO on Euronext Paris. The French pharmaceutical group specialising in the treatment of allergies was founded in 2002. DBV's proprietary technology Viaskin is used to administer an...



Berlin/Paris – Sanofi Pasteur has licensed a yeast strain from German Organobalance to produce vaccines. With the deal, the vaccines division of the French drugmaker will gain exclusive access to a modified strain of...

Displaying results 1 to 10 out of 268

1-10 Next >

© 2007-2015 BIOCOM


Current issue

All issues


All videos

Product of the week


Stock list

All quotes


  • ZELTIA (E)4.12 EUR22.99%
  • WILEX (D)2.20 EUR10.00%
  • DEINOVE (F)6.85 EUR7.54%


  • IMMUPHARMA (UK)28.50 GBP-12.98%
  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • THROMBOGENICS (B)4.08 EUR43.7%
  • OREXO (S)65.25 SEK40.9%
  • ZEALAND PHARMA (DK)155.00 DKK26.0%


  • THERAMETRICS (CH)0.04 CHF-33.3%
  • IMMUPHARMA (UK)28.50 GBP-30.1%


  • KARO BIO (S)43.10 SEK5221.0%
  • CHRONTECH PHARMA (S)0.34 SEK325.0%
  • GALAPAGOS (B)38.85 EUR237.5%


  • NEOVACS (F)0.72 EUR-76.7%
  • BIOTEST (D)19.00 EUR-74.8%
  • EVOCUTIS (UK)0.16 GBP-70.9%

No liability assumed, Date: 09.10.2015


All Events